36-Month Randomized Clinical Trial Evaluation of Preheated and Room Temperature Resin Composite

OBJECTIVE

This study evaluated the effect of preheating resin composites (RCs) on the clinical performance of class I restorations during a 36-month period using a split-mouth, double-blinded randomized design.

METHODS AND MATERIALS

A total of 35 patients were selected. Every patient received one pair of class I nanofilled resin composite (RC, Filtek Z350 XT) posterior restorations (n=70). One side of the mouth received preheated composites; on the other side, the composite was placed in a nonheated state following the manufacturer's instructions. These restorations were evaluated at 1-week (baseline), 12-months, 24-months, and 36-months using the FDI World Dental Federation criteria. The statistical analyses were also performed using the Wilcoxon and Friedman tests with the level of significance set at 0.05.

RESULTS

After 36 months, 33 patients attended the recall visits, and 66 restorations were evaluated. The Friedman and Wilcoxon signed-rank tests revealed insignificant differences between both groups (p>0.05) for all FDI parameters. However, a significant difference was detected for staining as a criterion at 36 months (p=0.01). Moreover, a significant difference in the staining was detected when the baseline and 36 months were compared in the nonheated RC group (p=0.001). For esthetic, functional, and biological properties, the nonheated composite exhibited 93.9%, 100%, and 100% of the clinically accepted scores, respectively, and the preheated group presented 100% for all properties. Four restorations had postoperative sensitivity at baseline for nonheated (11.4%) and five for preheated (14.2%), but the postoperative sensitivity scores were considered highly acceptable at 12-, 24-, and 36-months.

CONCLUSIONS

After 36 months, preheated nanofilled RCs showed an acceptable clinical performance similar to that of the nonheated ones in class I restorations, but with better resistance to marginal staining.

Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity

Unfortunately, COVID-19 is still a threat to humankind and has a dramatic impact on human health, social life, the world economy, and food security. With the limited number of suggested therapies under clinical trials, the discovery of novel therapeutic agents is essential. Here, a previously identified anti-SARS-CoV-2 compound named Compound 13 (1,2,5-Oxadiazole-3-carboximidic acid, 4,4'-(methylenediimino) bis,bis[[(2-hydroxyphenyl)methylene]hydrazide) was subjected to an iterated virtual screening against SARS-CoV-2 Mpro using a combination of Ligand Designer and PathFinder. PathFinder, a computational reaction enumeration tool, was used for the rapid generation of enumerated structures via default reaction library. Ligand designer was employed for the computerized lead optimization and selection of the best structural modification that resulted in a favorable ligand-protein complex. The obtained compounds that showed the best binding to Mpro were re-screened against TMPRSS2, leading to the identification of 20 shared compounds. The compounds were further visually inspected, which resulted in the identification of five shared compounds M1-5 with dual binding affinity. In vitro evaluation and enzyme inhibition assay indicated that M3, an analogue of Compound 13 afforded by replacing the phenolic moiety with pyridinyl, possesses an improved antiviral activity and safety. M3 displayed in vitro antiviral activity with IC50 0.016 µM and Mpro inhibition activity with IC50 0.013 µM, 7-fold more potent than the parent Compound 13 and potent than the antivirals drugs that are currently under clinical trials. Moreover, M3 showed potent activity against human TMPRSS2 and furin enzymes with IC50 0.05, and 0.08 µM, respectively. Molecular docking, WaterMap analysis, molecular dynamics simulation, and R-group analysis confirmed the superiority of the binding fit to M3 with the target enzymes. WaterMap analysis calculated the thermodynamic properties of the hydration site in the binding pocket that significantly affects the biological activity. Loading M3 on zinc oxide nanoparticles (ZnO NPs) increased the antiviral activity of the compound 1.5-fold, while maintaining a higher safety profile. In conclusion, lead optimized discovery following an iterated virtual screening in association with molecular docking and biological evaluation revealed a novel compound named M3 with promising dual activity against SARS-CoV-2. The compound deserves further investigation for potential clinical-based studies.

Retentiveness of metal coping luted to teeth of uremic patients undergoing hemodialysis using five different luting cements

OBJECTIVES

This study aimed to assess the retention of metal copings luted to uremic teeth with five different luting agents.

METHODS

A total of 35 sound natural molars was collected from uremic patients and randomly assigned into five groups (n=7). The teeth were prepared for metal copings using diamond tips and water coolant. Metal copings with a loop on the occlusal surface were fabricated using base metal alloy (Rexillium III). The copings were luted using Fuji I, glass ionomer (GI); Fuji Plus, resin-modified glass ionomer (RMGI); Panavia F 2.0, resin cement; Rely X Unicem, self-adhesive cement (SA); and Adhesor, zinc phosphate cement (ZPh). All specimens were incubated at 37°C for 24 hours, conditioned in artificial saliva for 7 days, and then thermocycled for 5000 cycles (5°C-55°C). The dislodging force was measured using a universal testing machine at a crosshead speed of 2 mm/min. The mode of failure of the loaded adhesive copings was evaluated. Statistical analyses were performed using one-way analysis of variance and Tukey post hoc test.

RESULTS

GI and SA cements had the highest and the lowest mean retentive strength, respectively (580.90±17.3, 406.6±12.7). There was no significant difference between ZPh, SA, and resin cements. These cements were inferior to GI and RMGI cements (p<0.05), which showed statistically similar retentive strengths.

CONCLUSIONS

The results of this study support the use of glass ionomer and resin-modified glass ionomer cements for luting of metal copings to uremic teeth with retentive preparations.

Clinical performance of ormocer, nanofilled, and nanoceramic resin composites in Class I and Class II restorations: a three-year evaluation

PURPOSE

This prospective long-term clinical trial evaluated and compared the three-year clinical performance of an ormocer, a nanofilled, and a nanoceramic resin composite with that of a microhybrid composite placed in Class I and Class II cavities.

METHODS

Forty patients, each with four Class I and II restorations under occlusion, were enrolled in this study. A total of 160 restorations were placed, 25% for each material, as follows: an ormocer-based composite, Admira; a nanofilled resin composite, Filtek Supreme XT; a nanoceramic resin composite, Ceram X; and a microhybrid resin composite, Tetric Ceram. A single operator placed all restorations according to the manufacturers' instructions. Immediately after placement the restorations were finished/polished. Clinical evaluation was performed at baseline and at yearly intervals after placement by two other independent examiners using modified US Public Health Service (USPHS) criteria. The changes in the USPHS parameters during the three-year period were analyzed with the Friedman test. Comparison of the baseline scores with those at the recall visits was made using the Wilcoxon signed rank test. The level of significance was set at p < 0.05.

RESULTS

All materials showed only minor changes, and no differences were detected between their performance at baseline and after three years. Only two ormocer, one nanofilled, and one microhybrid restorations in molars failed because of loss of retention. Regarding the clinical performance, there were no statistically significant differences among the materials used (p>0.05).

CONCLUSIONS

The ormocer, nanofilled, and nanoceramic composites provided acceptable clinical performance over a three-year period.

Preparation of C-(2-deoxyhex/pent-1-enopyranosyl)heterocycles

Acetylated 1-cyanoglycals (2,6-anhydro-3-deoxyhept/hex-2-enononitriles) were prepared by direct elimination of acetic acid from the appropriate acetylated 2,6-anhydrohept/hexononitriles with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) in aprotic solvents. Heterocyclisation of the cyano group of acetylated 1-cyano-D-galactal with 2-aminothiophenol led to 2-(3,4,6-tri-O-acetyl-2-deoxy-D-lyxo-hex-1-enopyranosyl)benz othiazole. Several 2-(per-O-acetylhexo/pentopyranosyl)benzothiazoles also gave 2-(per-O-acetyl-2-deoxyhex/pent-1-enopyranosyl)benzothiazole s with DBU. 3-(Per-O-acetylhexo/pentopyranosyl)-[1,2,4]triazolo[4,3-a] pyrimidines rearranged with DBU to the corresponding acetylated 2-glycosyl-[1,2,4]triazolo[1,5-a]pyrimidines. By the reaction of 1-cyano-D-galactal with ammonium azide, 2-(3,4,6-tri-O-acetyl-2-deoxy-D-lyxo-hex-1-enopyranosyl)tetr azole was prepared and then transformed with carboxylic acid derivatives into 2-(3,4,6-tri-O-acetyl-2-deoxy-D-lyxo-hex-1-enopyranosyl)-5-s ubstituted-1,3,4- oxadiazoles.

Inheritance and mapping of isoenzymes in pea (Pisum sativum L.)

Three isoenzyme systems (amylase, esterase and glutamate oxaloacetate transaminase) were examined in seeds of pea (Pisum sativum L.) and shown to give clear variation in their band patterns on gel electrophoresis between different lines. The inheritance of these isoenzyme systems, and the location of their genes on the pea genome was investigated. Reciprocal crosses were made between lines, F2 seeds were analysed for segregation in the band patterns of the isoenzymes, and F2 plants were investigated to find linkage between the genes for these isoenzymes and genes for selected morphological markers. The results obtained showed that each of the investigated isoenzyme systems is genetically controlled by co-dominant alleles at a single locus. The gene for amylase was found to be on chromosome 2, linked to the loci k and wb (wb ... 9 ... k ... 25 ... Amy). The gene for esterase was found to be linked with the gene Br (chromosome 4) but the exact location is uncertain because of the lack of the morphological markers involved in the cross. The gene for glutamate oxaloacetate transaminase was found to be on chromosome 1 and linked with the loci a and d (a... 24... Got... 41 ... d).